PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

Status:
Active, not recruiting

Trial end date:
2023-04-07

Target enrollment:

Participant gender:

This study will evaluate the efficacy and safety of pridopidine 45mg twice daily (BID) in patients with early stage manifest Huntington Disease (HD).

Phase 3

Prilenia